(Q47099469)

English

Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model

scientific article published on 15 September 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model (English)

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

osteogenesis imperfecta

0 references

author name string

Joseph E Perosky

1

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Basma M Khoury

2

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Terese N Jenks

3

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Ferrous S Ward

4

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Kai Cortright

5

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Bethany Meyer

6

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

David K Barton

7

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Benjamin P Sinder

8

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Joan C Marini

9

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Michelle S Caird

10

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Kenneth M Kozloff

11

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

publication date

15 September 2016

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

93

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

79-85

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Bisphosphonate therapy for osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Evaluation of teriparatide treatment in adults with osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

New perspectives on osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

23 May 2018

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Romosozumab in postmenopausal women with low bone mineral density.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

The paradox of prevention--bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Genetic variation in structure-function relationships for the inbred mouse lumbar vertebral body.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

15 August 2018

Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5077648

1 December 2018

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical fracture in a child with osteogenesis imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta

1 reference

https://pubmed.ncbi.nlm.nih.gov/27641475

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BONE.2016.09.013

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 January 2018

http://europepmc.org/abstract/PMC/5077648

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47099469&oldid=2141851699"